Prognosis of Acute Coronary Syndrome in HIV-infected Patients
Objectives: Evaluate differences for mortality, morbidity and the cardiovascular risk factors between HIV and non-HIV patients with an acute coronary syndromes (ACS) after a 3-years follow up.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Prognosis After Acute Coronary Syndrome in HIV-infected Patients|
- Comparison of the rate of Major Adverse Cardiac and Cerebrovascular Events between HIV+ and HIV- after a first episode of ACS after a 3-years follow up. [ Time Frame: 36 months ] [ Designated as safety issue: No ]
- Clinical, angiographic characteristics at baseline and comparison between HIV+ and HIV- [ Time Frame: 36 months ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Lipids, CRP, glycemia, insulinemia
|Study Start Date:||November 2003|
|Study Completion Date:||July 2010|
|Primary Completion Date:||July 2010 (Final data collection date for primary outcome measure)|
Background: There have been many cases of myocardial infarction reported in HIV-infected young adults treated with HAART. Little is known to date, concerning the outcome and prognostic factors of patients with acute coronary syndrome and HIV-infection.
Methods: Prospective cohort study to compare the evolution and prognosis between HIV and non-HIV patients with an ACS.
Duration of the study: Two years for including patients. Three years of follow-up 100 HIV-patients with ACS and 200 non-HIV patients with ACS will be included in the study. All patients will be included in the study from 30 Intensive Care Unit of Cardiology departments in France.
Results: To compare the incidence of total mortality, cardiovascular mortality (myocardial infarction, sudden death, cardiogenic shock, fatal stroke), morbidity (non fatal myocardial infarction, unstable angina, recurrence of ischemia, cardiac failure, non fatal stroke) and revascularization (percutaneous coronary intervention, coronary artery bypass graft surgery) during a 3-year follow-up between HIV and non-HIV patients with ACS. Univariate and multivariate analysis of predictive factors for cardiovascular events will be done.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00139958
|Paris, France, 75012|
|Study Chair:||Ariel Cohen, MD, PhD||Saint Antoine University Hospital|